"Epigenetic silencing of S100A2 in bladder and head and neck cancers" by Juna Lee, Piotr T. Wysocki et al.
 

Epigenetic silencing of S100A2 in bladder and head and neck cancers

Document Type

Article

Publication Title

Oncoscience

Abstract

100A2, a member of the S100 protein family, is known to be downregulated in a number of human cancers, leading to its designation as a potential tumor suppressor gene. Here, we investigated the expression and methylation status of S100A2 in head&neck and bladder cancer. Reduced mRNA and protein expression was observed in 8 head&neck and bladder cancer cell lines. To explore the mechanism responsible for the downregulation of S100A2, we treated six cell lines with 5-aza-2'-deoxycytidine. We found S100A2 is silenced in association with aberrant promoter-region methylation and its expression is restored with 5-aza-2'-deoxycytidine treatment. Of 31 primary head&neck cancer cases and 31 bladder cancer cases, promoter methylation was detected in 90% and 80% of cases, respectively. Interestingly, only 1/9 of normal head&neck tissues and 2/6 of normal bladder tissues showed promoter methylation. S100A2 promoter methylation can be detected in urine and is more frequent in bladder cancer patients than in healthy subjects (96% vs 48% respectively). Moreover, increased methylation of S100A2 is linked to the progression of the tumor in bladder cancer (p<0.01). Together, this data shows that methylation-associated inactivation of S100A2 is frequent and may be an important event in the tumorigenesis of head&neck and bladder cancer.

First Page

410

Last Page

418

DOI

https://doi.org/10.18632/oncoscience.140

Publication Date

3-16-2015

Link to Full Text

Plum Print visual indicator of research metrics
PlumX Metrics
  • Citations
    • Citation Indexes: 9
  • Usage
    • Abstract Views: 2
  • Captures
    • Readers: 8
  • Mentions
    • News Mentions: 1
see details

Share

COinS